Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Metformin vilagliptin tablets (II) (yiherui)

Combined with diet and exercise therapy, metformin is used in monotherapy for adults with type 2 diabetes mellitus who are still unable to control or are receiving treatment with veglerin and metformin. More role
App download minus 10 yuan
Common name:
Metformin vilagliptin tablets (II)
Product No.:
B14202802399
Approval No.:
H20171034 (original h20140926) (inquired by the State Drug Administration)
Jianke price:
¥209.00
Product specification:
850mg/50mg*30s
Manufacturer:
Novartis Pharma Schweiz AG
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Metformin vilagliptin tablets (II) (yiherui)
Main raw materials This product is a compound preparation. Its components are metformin hydrochloride and vigliptin. Active ingredient: metformin hydrochloride
Main role Combined with diet and exercise therapy, metformin is used in monotherapy for adults with type 2 diabetes mellitus who are still unable to control or are receiving treatment with veglerin and metformin.
Product specification 850mg/50mg*30s
Usage and dosage adult When this product is used for hypoglycemic treatment, the dose should be customized according to the patient's current treatment plan, curative effect and drug tolerance. However, the maximum daily dose of vigliptin shall not exceed the recommended 100mg. The usual administration regimen is twice a day, one tablet in the morning and one tablet in the evening. Taking this product at meals or after meals can reduce metformin gastrointestinal symptoms (see [pharmacokinetics]). For patients with the maximum tolerated dose of metformin monotherapy and poor blood glucose control, the initial dose of benchang is equivalent to 50 mg of vilagliptin twice a day (total daily dose of 100 mg), plus the dose of metformin being taken. (see instructions for details)
manufacturing enterprise Novartis Pharma Schweiz AG
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Metformin vilagliptin tablets (II) (yiherui)

[common name] Metformin vilagliptin tablets (II)

[specification and model] 850mg/50mg*30s

[manufacturer] Novartis Pharma Schweiz AG

[drug type] Western medicine

[approval No.] H20171034 (original h20140926)

[validity period] 24 months

[functional indications] Combined with diet and exercise therapy, metformin is used in monotherapy for adults with type 2 diabetes mellitus who are still unable to control or are receiving treatment with veglerin and metformin.

[usage and dosage] adult When this product is used for hypoglycemic treatment, the dose should be customized according to the patient's current treatment plan, curative effect and drug tolerance. However, the maximum daily dose of vigliptin shall not exceed the recommended 100mg. The usual administration regimen is twice a day, one tablet in the morning and one tablet in the evening. Taking this product at meals or after meals can reduce metformin gastrointestinal symptoms (see [pharmacokinetics]). For patients with the maximum tolerated dose of metformin monotherapy and poor blood glucose control, the initial dose of benchang is equivalent to 50 mg of vilagliptin twice a day (total daily dose of 100 mg), plus the dose of metformin being taken. (see instructions for details)

[adverse reactions] There is no clinical efficacy test data of this product, but the test shows that this product is bioequivalent with the combined application of vilagliptin and metformin. The following data comes from the study of the combined application of vilagliptin and metformin tablets. In this study, vilagliptin tablets are used as an additional therapeutic drug of metformin tablets. There is no study on the addition of metformin in the treatment of vilagliptin. (see instructions for details)

[precautions] For patients who need insulin treatment, this product cannot replace insulin. This product is not suitable for patients with type 1 diabetes. (see the instructions for details) please read the instructions carefully and follow the doctor's instructions.

[taboo] 1. Those who are known to be allergic to vigliptin, metformin or any component of this product. 2. lactic acidosis, diabetic ketoacidosis or prediabetic patients. 3. Severe renal insufficiency (EGFR < 45ml / (min.1.73m2) Patients, as well as patients with other acute diseases that can change renal function (such as dehydration, severe infection, shock or intravascular injection of iodine contrast agent). 4. Patients with acute or chronic diseases that can cause tissue hypoxia, such as heart failure or respiratory failure, recent myocardial infarction and shock. 5. Patients with liver dysfunction with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal (ULN). 6. Patients with alcoholism. 7. Lactating women.

[listing Permit Holder] NovartisPharmaSchweizAG

[packaging unit] box

[main ingredients] This product is a compound preparation. Its components are metformin hydrochloride and vigliptin. Active ingredient: metformin hydrochloride

[character] This product is a yellow film coated tablet, which turns white after removing the coating.

[applicable population] adult

[medication for pregnant and lactating women] gestation There are few data on the use of this product in pregnant women. The results of animal experiments showed that high-dose vilagliptin had reproductive toxicity, while metformin had no reproductive toxicity. It was found in animal experiments on vigliptin and metformin that neither of the two drugs has teratogenicity, but the toxicity of the drugs to fetuses can be observed at the dose level without toxicity to parent animals (see [pharmacology and toxicology]). The potential risk of this product to humans is unknown. This product is forbidden during pregnancy. lactation The results of animal experiments show that metformin and vigliptin can be secreted through milk. At present, it is not known whether vigliptin is secreted through milk in humans: metformin can be secreted through milk, but the secretion is low. Due to the risk of metformin leading to neonatal hypoglycemia and the limited accumulation of data on the application of vigliptin in humans, this product cannot be used during lactation (see [contraindications]). fertility This study has not been conducted and there are no reliable references.

[medication for children] This product is not recommended for children and adolescents (< 18 years old). The safety and efficacy of this product in adolescents and children under the age of 18 have not been determined, and there is no reliable reference.

[medication for elderly patients] For the elderly (≥ 65 years old), because metformin is excreted through the kidney, and the elderly may have weakened renal function, the elderly patients should regularly monitor their renal function when using products containing metformin (such as this product). The dose of this product should be adjusted according to the renal function of elderly patients (see [usage and dosage], [contraindication] and [pharmacokinetics]).

[storage] Sealed, dry place at normal temperature

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Metformin vilagliptin tablets (II) (yiherui)

    ¥209.00

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!